Role of ‘Aviptadil’ in Treatment of Acute Respiratory Distress Syndrome (ARDS): Case Series
Year: 2025
Type: article
Study design: Case Report
Abstract: As we know respiratory failure is a lethal complication of viral illnesses that has remained resistant to conventional treatment and ventilator support. Acute respiratory distress syndrome is life-threatening scenario that requires ICU admissions. Treating this condition requires proper oxygenation strategies with mechanical ventilation and positive pressure (PEEP) to recruit alveoli. Vasoactive intestinal peptide (Aviptadil) is shown in literature to up regulate surfactant production, inhibit cytokine synthesis, prevent cytopathic effects and block replication of viral cells in pulmonary cells. Human vasoactive intestinal peptide prevents further lung injury and reduces inflammation. We share our observation and experience via this case series regarding effective and safe use of aviptadil for treating ARDS arising from viral illnesses and others apart from its previous benefits found in COVID19 related ARDS cases. How to cite this article: Gupta S, Deshpande S, Raul K, Pramanik V, Navpute K, Solanke O. Role of ‘Aviptadil’ in Treatment of Acute Respiratory Distress Syndrome (ARDS): Case Series. J Adv Res Med Sci Tech. 2025;12(1&2):15-21. DOI: https://doi.org/10.24321/2394.6539.202503
Author: Sagar Gupta
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4414036510